首页> 美国卫生研究院文献>BioMed Research International >Placental Leucine Aminopeptidase- and Aminopeptidase A- Deficient Mice Offer Insight concerning the Mechanisms Underlying Preterm Labor and Preeclampsia
【2h】

Placental Leucine Aminopeptidase- and Aminopeptidase A- Deficient Mice Offer Insight concerning the Mechanisms Underlying Preterm Labor and Preeclampsia

机译:胎盘亮氨酸氨基肽酶和氨基肽酶A缺陷型小鼠提供了有关早产和先兆子痫的潜在机制的见解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Preeclampsia and preterm delivery are important potential complications in pregnancy and represent the leading causes for maternal and perinatal morbidity and mortality. The mechanisms underlying both diseases remain unknown, thus available treatments (beta2-stimulants and magnesium sulfate) are essentially symptomatic. Both molecules have molecular weights less than 5–8 kDa, cross the placental barrier, and thus exert their effects on the fetus. The fetus produces peptides that are highly vasoactive and uterotonic and increase in response to maternal stress and with continued development. Fetal peptides are also small molecules that inevitably leak across into the maternal circulation. Aminopeptidases such as placental leucine aminopeptidase (P-LAP) and aminopeptidase A (APA) are large molecules that do not cross the placental barrier. We have shown that APA acts as an antihypertensive agent in the pregnant spontaneously hypertensive rat by degrading vasoactive peptides and as a result returns the animal to a normotensive state. P-LAP also acts as an antiuterotonic agent by degrading uterotonic peptides and thus prolongs gestation in the pregnant mouse. Given the ever increasing worldwide incidences of preeclampsia and preterm labor, it is imperative that new agents be developed to safely prolong gestation. We believe that the use of aminopeptidases hold promise in this regard.
机译:子痫前期和早产是妊娠中重要的潜在并发症,并且是孕产妇和围产儿发病和死亡的主要原因。两种疾病的潜在机制仍然未知,因此可用的治疗方法(β2-兴奋剂和硫酸镁)基本上是对症治疗。两个分子的分子量均小于5-8kDa,穿过胎盘屏障,因此对胎儿产生影响。胎儿产生的肽具有高度的血管活性和子宫收缩能力,并响应母体压力并持续发育而增加。胎儿肽也是不可避免地渗漏到母体循环中的小分子。氨基肽酶,例如胎盘亮氨酸氨基肽酶(P-LAP)和氨基肽酶A(APA)是不会穿过胎盘屏障的大分子。我们已经表明,APA通过降解血管活性肽而在妊娠自发性高血压大鼠中作为降压药,从而使动物恢复为正常血压状态。 P-LAP还可以通过降解子宫缩蛋白肽而作为抗子宫缩蛋白剂,从而延长妊娠小鼠的妊娠期。鉴于世界范围内先兆子痫和早产的发病率不断上升,必须开发新的药物来安全延长妊娠。我们相信在这方面使用氨基肽酶是有希望的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号